Patents by Inventor Gary K. Schwartz
Gary K. Schwartz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230037014Abstract: A method of preventing metastasis of a cancer in a patient in need thereof includes administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.Type: ApplicationFiled: July 25, 2022Publication date: February 2, 2023Applicants: MediciNova, Inc., The Trustees of Columbia University in the City of New YorkInventors: Kazuko Matsuda, Grazia Ambrosini, Gary K. Schwartz, Alex J. Rai
-
Patent number: 11518996Abstract: The present invention provides compositions and methods for treating cancer with peptide nucleic acid agents. In some embodiments, the present invention provides methods and compositions relating to peptide nucleic acid agents that target oncogenes. For example, the present invention provides compositions, including pharmaceutical compositions, comprising agents specific for BRAF V600E inhibition, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using BRAF V600E specific peptide nucleic acid agents and/or compositions.Type: GrantFiled: August 7, 2020Date of Patent: December 6, 2022Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Jeffrey H. Rothman, Gary K. Schwartz
-
Patent number: 10858655Abstract: The present invention provides compositions and methods for treating cancer with peptide nucleic acid agents. In some embodiments, the present invention provides methods and compositions relating to peptide nucleic acid agents that target oncogenes. For example, the present invention provides compositions, including pharmaceutical compositions, comprising agents specific for BRAF V600E inhibition, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using BRAF V600E specific peptide nucleic acid agents and/or compositions.Type: GrantFiled: October 29, 2018Date of Patent: December 8, 2020Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Jeffrey H. Rothman, Gary K. Schwartz
-
Publication number: 20200370049Abstract: The present invention provides compositions and methods for treating cancer with peptide nucleic acid agents. In some embodiments, the present invention provides methods and compositions relating to peptide nucleic acid agents that target oncogenes. For example, the present invention provides compositions, including pharmaceutical compositions, comprising agents specific for BRAF V600E inhibition, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using BRAF V600E specific peptide nucleic acid agents and/or compositions.Type: ApplicationFiled: August 7, 2020Publication date: November 26, 2020Inventors: Jeffery H. Rothman, Gary K. Schwartz
-
Publication number: 20190376149Abstract: The present invention relates to methods and compositions for determining the likelihood that a subject suffering from a cancer will benefit from treatment with a MEK inhibitor. It also relates to methods of treatment based on such determination. The invention is based, at least in part, on the discoveries that DDX43 mRNA and protein are expressed at high levels in biopsies from “non-responder” UM patients and that selumetinib-resistant cell lines showed high DDX43 expression which correlated with increased expression and activity of RAS. It was found that KRAS and HRAS but not NRAS, mediated expression of pERK and pAKT, bypassing oncogenic GNAQ. The invention is further based on the discovery that selumetinib-resistant cells became sensitive to AKT inhibition, suggesting alternative strategies for the treatment of cancer patients with acquired resistance to MEK inhibitors.Type: ApplicationFiled: July 23, 2019Publication date: December 12, 2019Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Grazia Ambrosini, Raya Khanin, Richard Carvajal, Gary K. Schwartz
-
Publication number: 20190284561Abstract: The present invention provides compositions and methods for treating cancer with peptide nucleic acid agents. In some embodiments, the present invention provides methods and compositions relating to peptide nucleic acid agents that target oncogenes. For example, the present invention provides compositions, including pharmaceutical compositions, comprising agents specific for BRAF V600E inhibition, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using BRAF V600E specific peptide nucleic acid agents and/or compositions.Type: ApplicationFiled: October 29, 2018Publication date: September 19, 2019Inventors: Jeffrey H. Rothman, Gary K. Schwartz
-
Patent number: 10400285Abstract: The present invention relates to methods and compositions for determining the likelihood that a subject suffering from a cancer will benefit from treatment with a MEK inhibitor. It also relates to methods of treatment based on such determination. The invention is based, at least in part, on the discoveries that DDX43 mRNA and protein are expressed at high levels in biopsies from “non-responder” UM patients and that selumetinib-resistant cell lines showed high DDX43 expression which correlated with increased expression and activity of RAS. It was found that KRAS and HRAS but not NRAS, mediated expression of pERK and pAKT, bypassing oncogenic GNAQ. The invention is further based on the discovery that selumetinib-resistant cells became sensitive to AKT inhibition, suggesting alternative strategies for the treatment of cancer patients with acquired resistance to MEK inhibitors.Type: GrantFiled: March 4, 2016Date of Patent: September 3, 2019Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Grazia Ambrosini, Raya Khanin, Richard Carvajal, Gary K. Schwartz
-
Patent number: 10113169Abstract: The present invention provides compositions and methods for treating cancer with peptide nucleic acid agents. In some embodiments, the present invention provides methods and compositions relating to peptide nucleic acid agents that target oncogenes. For example, the present invention provides compositions, including pharmaceutical compositions, comprising agents specific for BRAF V600E inhibition, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using BRAF V600E specific peptide nucleic acid agents and/or compositions.Type: GrantFiled: December 17, 2014Date of Patent: October 30, 2018Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Jeffrey H. Rothman, Gary K. Schwartz
-
Patent number: 9889135Abstract: The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. It is based, at least in part, on the discovery that cancer treatment with a CDK4 inhibitor is more effective where treated cancer cells undergo cellular senescence rather than a transient cell cycle arrest, where cellular senescence is associated with decreased MDM2 protein level. Accordingly, in non-limiting embodiments, the present invention provides for methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, and in particular, to the use of MDM2 expression as a biomarker for the likelihood that a cancer can be successfully treated by CDK4 inhibition.Type: GrantFiled: October 15, 2015Date of Patent: February 13, 2018Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Andrew Koff, Aimee Crago, David Liu, Marta Kovatcheva, Samuel Singer, Gary K. Schwartz, Mark A. Dickson, Mary Elizabeth Klein
-
Publication number: 20160319284Abstract: The present invention provides compositions and methods for treating cancer with peptide nucleic acid agents. In some embodiments, the present invention provides methods and compositions relating to peptide nucleic acid agents that target oncogenes. For example, the present invention provides compositions, including pharmaceutical compositions, comprising agents specific for BRAF V600E inhibition, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using BRAF V600E specific peptide nucleic acid agents and/or compositions.Type: ApplicationFiled: December 17, 2014Publication date: November 3, 2016Inventors: Jeffrey K. Rothman, Gary K. Schwartz
-
Publication number: 20160258027Abstract: The present invention relates to methods and compositions for determining the likelihood that a subject suffering from a cancer will benefit from treatment with a MEK inhibitor. It also relates to methods of treatment based on such determination. The invention is based, at least in part, on the discoveries that DDX43 mRNA and protein are expressed at high levels in biopsies from “non-responder” UM patients and that selumetinib-resistant cell lines showed high DDX43 expression which correlated with increased expression and activity of RAS. It was found that KRAS and HRAS but not NRAS, mediated expression of pERK and pAKT, bypassing oncogenic GNAQ. The invention is further based on the discovery that selumetinib-resistant cells became sensitive to AKT inhibition, suggesting alternative strategies for the treatment of cancer patients with acquired resistance to MEK inhibitors.Type: ApplicationFiled: March 4, 2016Publication date: September 8, 2016Applicant: Memorial Sloan-Kettering Cancer CenterInventors: Grazia Ambrosini, Raya Khanin, Richard Carvajal, Gary K. Schwartz
-
Publication number: 20160030433Abstract: The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. It is based, at least in part, on the discovery that cancer treatment with a CDK4 inhibitor is more effective where treated cancer cells undergo cellular senescence rather than a transient cell cycle arrest, where cellular senescence is associated with decreased MDM2 protein level. Accordingly, in non-limiting embodiments, the present invention provides for methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, and in particular, to the use of MDM2 expression as a biomarker for the likelihood that a cancer can be successfully treated by CDK4 inhibition.Type: ApplicationFiled: October 15, 2015Publication date: February 4, 2016Applicant: Memorial Sloan-Kettering Cancer CenterInventors: Andrew Koff, Aimee Crago, David Liu, Marta Kovatcheva, Samuel Singer, Gary K. Schwartz, Mark A. Dickson, Mary Elizabeth Klein
-
Patent number: 7045495Abstract: This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.Type: GrantFiled: August 7, 2002Date of Patent: May 16, 2006Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Gary K. Schwartz, Anthony P. Albino
-
Publication number: 20040219508Abstract: This invention provides a method for screening a mixture of compounds for activity comprising steps of contacting the mixture with a system which mimics an organ capable of metabolizing the mixture in an appropriate time to generate a metabolite; and determining the activity of the generated metabolite. This invention also provides a method for quantitating a mixture of compounds comprising steps of contacting the mixture with a system which mimics an organ capable of metabolizing the mixture in an appropriate time to generate a metabolite; and determining the activity of the generated metabolite. This invention further provides a method for identifying an active metabolite from a mixture of compounds comprising steps of contacting the mixture with a system which mimics an organ capable of metabolizing the mixture in an appropriate time to generate a metabolite; and determining the activity of the metabolite generated. Finally, this invention provides various uses of this method and the identified metabolite.Type: ApplicationFiled: October 24, 2003Publication date: November 4, 2004Applicant: Sloan-Kettering Institute for Cancer ResearchInventor: Gary K. Schwartz
-
Publication number: 20030199469Abstract: This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.Type: ApplicationFiled: August 7, 2002Publication date: October 23, 2003Applicant: Sloan - Kettering Institute for Cancer ResearchInventors: Gary K. Schwartz, Anthony P. Albino
-
Patent number: 6444638Abstract: This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.Type: GrantFiled: August 20, 1998Date of Patent: September 3, 2002Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Gary K. Schwartz, Anthony P. Albino
-
Publication number: 20010011076Abstract: This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.Type: ApplicationFiled: August 20, 1998Publication date: August 2, 2001Inventors: GARY K. SCHWARTZ, ANTHONY P. ALBINO
-
Patent number: 5821072Abstract: This invention provides methods for screening protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.Type: GrantFiled: February 20, 1996Date of Patent: October 13, 1998Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Gary K. Schwartz, Anthony P. Albino